Evolocumab在中欧和东欧的LDL-C水平比指南中推荐的高得多的患者中开始使用:观察性HEYMANS研究的结果。

IF 3.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
V Blaha, R Margoczy, I Petrov, A Postadzhiyan, K Raslova, H Rosolova, I Bridges, N N Dhalwani, M Zachlederova, K K Ray
{"title":"Evolocumab在中欧和东欧的LDL-C水平比指南中推荐的高得多的患者中开始使用:观察性HEYMANS研究的结果。","authors":"V Blaha, R Margoczy, I Petrov, A Postadzhiyan, K Raslova, H Rosolova, I Bridges, N N Dhalwani, M Zachlederova, K K Ray","doi":"10.15420/ecr.2023.18.PO19","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e36"},"PeriodicalIF":3.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d9/cb/ecr-18-e36.PMC10316339.pdf","citationCount":"0","resultStr":"{\"title\":\"Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than Recommended in Guidelines: Results from the Observational HEYMANS Study.\",\"authors\":\"V Blaha, R Margoczy, I Petrov, A Postadzhiyan, K Raslova, H Rosolova, I Bridges, N N Dhalwani, M Zachlederova, K K Ray\",\"doi\":\"10.15420/ecr.2023.18.PO19\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":45957,\"journal\":{\"name\":\"European Cardiology Review\",\"volume\":\"18 \",\"pages\":\"e36\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d9/cb/ecr-18-e36.PMC10316339.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Cardiology Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15420/ecr.2023.18.PO19\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Cardiology Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15420/ecr.2023.18.PO19","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than Recommended in Guidelines: Results from the Observational HEYMANS Study.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
European Cardiology Review
European Cardiology Review CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
5.40
自引率
0.00%
发文量
23
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信